Anglia Ruskin Research Online (ARRO)
Browse
Reviews in Medical Virology - 2024 - Cho - Clinical characteristics and outcomes of patients with mpox during the 2022 mpox.pdf (679.52 kB)

Clinical characteristics and outcomes of patients with mpox during the 2022 mpox outbreak compared with those before the outbreak: A systematic review and meta-analysis

Download (679.52 kB)
journal contribution
posted on 2024-02-12, 16:25 authored by Wonyoung Cho, Sangil Park, Hyeon Jin Kim, Myeongcheol Lee, Yong Sung Choi, Seung Geun Yeo, Jinseok Lee, Ai Koyanagi, Louis Jacob, Lee Smith, Masoud Rahmati, Suhana Ahmad, Guillaume Fond, Laurent Boyer, Sang Youl Rhee, Seung Won Lee, Jae Il Shin, Ho Geol Woo, Dong Keon Yon

On 23 July 2022, the World Health Organization declared the global mpox outbreak as a public health emergency of international significance. The mpox virus (MPXV) that caused the outbreak was classified as clade IIb, which belongs to the West African clade. However, the relationship between MPXV clades and symptoms, as well as the severity of mpox outcomes, is not fully understood. Thus, we aimed to investigate the global mpox prevalence and the differences in clinical manifestations and outcomes among patients with mpox between pre‐outbreak (2003–2021) and the current mpox outbreak. In this systematic review and meta‐analysis, PubMed/MEDLINE, Web of Science, Embase, Cumulative Index to Nursing and Allied Health Literature, and Google Scholar were searched using the keyword “monkeypox” and “mpox” up to 13 October 2022. A random effects model was used to obtain the pooled prevalence and 95% confidence intervals. This study included 27 articles, and 5698 patients with mpox with 19 distinctive features from 19 countries across five continents were assessed. Patients with mpox during the 2022 mpox outbreak showed mild clinical manifestations and outcomes compared with those before the 2022 mpox outbreak: mild rash (relative ratio [RR]: 5.09, 95% confidence interval [CI]: 1.52–17.08), fever (0.68, 0.49–0.94), pruritus (0.25, 0.19–0.32), myalgia (0.50, 0.31–0.81), headache (0.56, 0.35–0.88), skin ulcer (0.32, 0.17–0.59), abdominal symptom (0.29, 0.20–0.42), pharyngitis (0.32, 0.18–0.58), nausea or vomiting (0.15, 0.02–0.93), conjunctivitis (0.11, 0.03–0.38), concomitant infection with HIV (1.70, 0.95–3 0.04), and death (0.02, 0.001–0.31). MPXV clade IIb exhibited higher infectivity but may cause mild disease symptoms and low mortality rate. It is important to consider MPXV infection in patients with mpox‐related features and/or a history of sexual transmission to prevent the spread of the disease and recognise the current pandemic threat.

History

Refereed

  • Yes

Volume

34

Issue number

1

Publication title

Reviews in Medical Virology

ISSN

1052-9276

Publisher

Wiley

File version

  • Published version

Item sub-type

Article

Affiliated with

  • School of Psychology and Sport Science Outputs

Usage metrics

    ARU Outputs

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC